drugset / Trial / NCT03829007
PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC
NaSingle-groupOpen-labelDiagnostic
Summary
Non-invasive imaging of tumor PD-L1 expression with 89Zr-labeled durvalumab PET/CT predicts response to durvalumab.
Timeline
- Start
- 2019-04-15
- Primary completion
- 2020-12-17
- Completion
- 2021-12-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |